Net debt/EBITDA společnosti Cue Biopharma Inc
Jaká je hodnota metriky Net debt/EBITDA společnosti Cue Biopharma Inc?
Hodnota metriky Net debt/EBITDA společnosti Cue Biopharma Inc je 2.57
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Cue Biopharma Inc
Čemu se věnuje společnost Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Firmy s metrikou net debt/ebitda podobnou společnosti Cue Biopharma Inc
- Hodnota metriky Net debt/EBITDA společnosti Egdon Resources plc je 2.56
- Hodnota metriky Net debt/EBITDA společnosti Helmerich & Payne je 2.56
- Hodnota metriky Net debt/EBITDA společnosti ABB Ltd je 2.57
- Hodnota metriky Net debt/EBITDA společnosti Bel Fuse je 2.57
- Hodnota metriky Net debt/EBITDA společnosti Podium Minerals je 2.57
- Hodnota metriky Net debt/EBITDA společnosti InVivo Therapeutics Corp je 2.57
- Hodnota metriky Net debt/EBITDA společnosti Cue Biopharma Inc je 2.57
- Hodnota metriky Net debt/EBITDA společnosti Emerald Resources NL je 2.57
- Hodnota metriky Net debt/EBITDA společnosti Accell NV je 2.57
- Hodnota metriky Net debt/EBITDA společnosti Accell N.V je 2.57
- Hodnota metriky Net debt/EBITDA společnosti Pci Pal Plc je 2.58
- Hodnota metriky Net debt/EBITDA společnosti Auryn Resources je 2.58
- Hodnota metriky Net debt/EBITDA společnosti United (Martins Ferry, OH) je 2.58